Atheronova Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2009
2010
2011
2012
2013
Cost of Goods Sold (COGS) incl. D&A
-
1.50
381.50
-
-
Gross Income
-
1.50
381.50
-
-
SG&A Expense
141.30
2,105.00
2,178.70
3,634.60
7,210.00
EBIT
141.30
2,106.60
2,560.20
3,638.00
7,214.20
Unusual Expense
-
13,200.00
7,486.90
1,872.40
-
Non Operating Income/Expense
-
1.40
0.40
2.80
2.50
Interest Expense
55.10
349.90
658.20
871.40
601.70
Pretax Income
196.40
15,655.10
4,268.90
2,634.20
7,813.40
Income Tax
-
1.80
5.60
1.40
1.40
Consolidated Net Income
196.40
15,656.90
4,263.30
2,635.60
7,814.70
Net Income
196.40
15,656.90
4,263.30
2,635.60
7,814.70
Net Income After Extraordinaries
196.40
15,656.90
4,263.30
2,635.60
7,814.70
Net Income Available to Common
196.40
15,656.90
4,263.30
2,635.60
7,814.70
EPS (Basic)
4.40
7.00
1.50
0.90
1.97
Basic Shares Outstanding
44.60
2,244.10
2,556.40
3,063.50
3,973.00
EPS (Diluted)
4.40
6.98
1.49
0.86
1.97
Diluted Shares Outstanding
44.60
2,244.10
2,866.60
3,063.50
3,973.00
EBITDA
141.30
2,105.00
2,557.70
3,634.60
7,210.00

About Atheronova

View Profile
Address
2301 Dupont Drive
Irvine California 92612
United States
Employees -
Website -
Updated 07/08/2019
AtheroNova, Inc. is a biotechnology company. The company engages in the research and development, marketing, and sale of pharmaceutical preparations and pharmaceutical intellectual property. It develops intellectual property that uses certain pharmacological compounds for the treatment of atherosclerosis, which is the primary cause of various cardiovascular diseases.